Taina Sipponen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Taina Sipponen has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
- Martti Färkkilä
Clinic of Gastroenterology, Helsinki University Hospital, Helsinki, Finland
13 shared publications Kaija-Leena Kolho
8 shared publicationsPerttu Arkkila
University of Helsinki, Helsinki
7 shared publicationsTimo Blomster
Department of Medicine, Division of Gastroenterology, Oulu University Hospital, Oulu, Finland
7 shared publicationsAiri Jussila
Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland
6 shared publicationsHenna Rautiainen
Department of Gastroenterology, Helsinki University Hospital/Jorvi Hospital, Espoo, Finland
6 shared publications
Latest Publications
- Open Access
- 5 December 2025
- Published by Microbiology Society in Journal of General Virology
- Vol. 106 (12) , 002184
Genoprevalence of cutavirus in benign and malignant intestinal and breast tissues
Cutavirus (CuV), the newest human protoparvovirus (PPV), has gained attention due to its significant association with cutaneous T-cell lymphoma (CTCL) and its precursor, parapsoriasis, whereas the other human PPVs, bufavirus and tusavirus, show no such link. Given this association, it is important to investigate the prevalence of CuV DNA in other tissues, particularly those affected by malignancy or inflammation. This study assessed, by multiplex quantitative PCR, the genoprevalences of all three PPVs in 427 fresh-frozen intestinal biopsies from inflammatory bowel disease (IBD), colorectal cancer, adenomas or healthy mucosa of 185 individuals, as well as in 94 formalin-fixed paraffin-embedded (FFPE) biopsies from malignant and non-malignant breast conditions of 85 patients. The study also compared the DNA prevalences of human herpesvirus (HHV)-6A, -6B and -7 in the breast tissues. CuV mRNA was assayed with reverse-transcription PCR, and corresponding FFPE sections underwent in situ hybridization. CuV DNA was detected in intestinal IBD or healthy mucosa from 6/185 (3.2%) subjects, but no CuV mRNA or in situ signals were detected. In breast biopsies, HHV-6B and HHV-7 DNAs were present in 20.3 and 5.1%, respectively, while all PPVs and HHV-6A were absent. Overall, CuV was absent in all 70 cancer tissues, underscoring its association with CTCL. The low CuV DNA loads and prevalences in intestinal and breast morbidities, and lack of activity, suggest that CuV is unlikely to play a role in these malignancies or inflammatory conditions. In contrast, HHV-6B may be more relevant to breast pathology, even though it is also widely detected in healthy tissues. Nevertheless, our study provides insight into persistent DNA viruses implicated in cancer and highlights their occurrence across various disease manifestations, laying a foundation for future studies.
- 5 December 2025
- Published by Microbiology Society in Journal of General Virology
- Vol. 106 (12) , 002184
Open AccessGenoprevalence of cutavirus in benign and malignant intestinal and breast tissues
Cutavirus (CuV), the newest human protoparvovirus (PPV), has gained attention due to its significant association with cutaneous T-cell lymphoma (CTCL) and its precursor, parapsoriasis, whereas the other human PPVs, bufavirus and tusavirus, show no such link. Given this association, it is important to investigate the prevalence of CuV DNA in other tissues, particularly those affected by malignancy or inflammation. This study assessed, by multiplex quantitative PCR, the genoprevalences of all three PPVs in 427 fresh-frozen intestinal biopsies from inflammatory bowel disease (IBD), colorectal cancer, adenomas or healthy mucosa of 185 individuals, as well as in 94 formalin-fixed paraffin-embedded (FFPE) biopsies from malignant and non-malignant breast conditions of 85 patients. The study also compared the DNA prevalences of human herpesvirus (HHV)-6A, -6B and -7 in the breast tissues. CuV mRNA was assayed with reverse-transcription PCR, and corresponding FFPE sections underwent in situ hybridization. CuV DNA was detected in intestinal IBD or healthy mucosa from 6/185 (3.2%) subjects, but no CuV mRNA or in situ signals were detected. In breast biopsies, HHV-6B and HHV-7 DNAs were present in 20.3 and 5.1%, respectively, while all PPVs and HHV-6A were absent. Overall, CuV was absent in all 70 cancer tissues, underscoring its association with CTCL. The low CuV DNA loads and prevalences in intestinal and breast morbidities, and lack of activity, suggest that CuV is unlikely to play a role in these malignancies or inflammatory conditions. In contrast, HHV-6B may be more relevant to breast pathology, even though it is also widely detected in healthy tissues. Nevertheless, our study provides insight into persistent DNA viruses implicated in cancer and highlights their occurrence across various disease manifestations, laying a foundation for future studies.
- Open Access
- 13 February 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (4) , 1457-1466
Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease
Background Recent studies suggest that subcutaneous infliximab is effective and safe for treating patients with inflammatory bowel disease. Real-world studies with larger cohorts are needed to confirm the efficacy of subcutaneous treatment. Aims The aim was to assess real-world treatment persistence, clinical outcomes, infliximab concentrations, and treatment safety after switching from intravenous to subcutaneous infliximab treatment with patients with inflammatory bowel disease. Methods This retrospective register-based study included patients with inflammatory bowel disease who were in clinical remission and switched from intravenous infliximab maintenance therapy to subcutaneous infliximab in two tertiary centers. Results A total of 274 patients (104 Crohn's disease and 170 ulcerative colitis) were included. After the switch, the treatment persistence at 12 months was 94.8% in patients with Crohn’s disease and 88.8% in patients with ulcerative colitis. Only 11.3% (n = 31) of the patients discontinued the treatment during 79-week median follow-up. Compared to the baseline, no change occurred in clinical disease activity at the time points of 3, 6, and 12 months, based on the Harvey–Bradshaw Index or partial Mayo Score (p = 0.792 and p = 0.426, respectively). Infliximab median concentrations were higher (p < 0.0001) during subcutaneous treatment (16.75 µg/ml) compared to the intravenous treatment median trough levels before the switch (6.71 µg/ml). In total, 15.0% (n = 41) of the patients reported adverse events. Conclusion Switching to subcutaneous infliximab maintenance therapy was associated with high treatment persistence, a stable disease course, increased infliximab concentrations, and an acceptable safety profile.
- 13 February 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (4) , 1457-1466
Open AccessSwitching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease
Background Recent studies suggest that subcutaneous infliximab is effective and safe for treating patients with inflammatory bowel disease. Real-world studies with larger cohorts are needed to confirm the efficacy of subcutaneous treatment. Aims The aim was to assess real-world treatment persistence, clinical outcomes, infliximab concentrations, and treatment safety after switching from intravenous to subcutaneous infliximab treatment with patients with inflammatory bowel disease. Methods This retrospective register-based study included patients with inflammatory bowel disease who were in clinical remission and switched from intravenous infliximab maintenance therapy to subcutaneous infliximab in two tertiary centers. Results A total of 274 patients (104 Crohn's disease and 170 ulcerative colitis) were included. After the switch, the treatment persistence at 12 months was 94.8% in patients with Crohn’s disease and 88.8% in patients with ulcerative colitis. Only 11.3% (n = 31) of the patients discontinued the treatment during 79-week median follow-up. Compared to the baseline, no change occurred in clinical disease activity at the time points of 3, 6, and 12 months, based on the Harvey–Bradshaw Index or partial Mayo Score (p = 0.792 and p = 0.426, respectively). Infliximab median concentrations were higher (p < 0.0001) during subcutaneous treatment (16.75 µg/ml) compared to the intravenous treatment median trough levels before the switch (6.71 µg/ml). In total, 15.0% (n = 41) of the patients reported adverse events. Conclusion Switching to subcutaneous infliximab maintenance therapy was associated with high treatment persistence, a stable disease course, increased infliximab concentrations, and an acceptable safety profile.
- 10 September 2022
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 34 (11) , 1125-1131
Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease
Objective: Measuring of serum infliximab (IFX) induction concentrations might reduce primary non-response rates in inflammatory bowel diseases (IBD), but optimal target concentrations are unclear. We investigated whether IFX induction concentrations predict short-term endoscopic response at week 12 or treatment persistence at week 52. Methods: Sixty-nine IBD patients (Crohn’s disease, n=24; ulcerative colitis, n=45) received standard IFX induction of 5 mg/kg bodyweight at weeks 0, 2, and 6. Responders continued maintenance therapy and underwent follow-up until week 52 or treatment discontinuation. We measured IFX concentrations at weeks 2, 6, and 12, and evaluated treatment response around week 12 with endoscopy or with clinical scores and fecal calprotectin. Using the receiver operating characteristic analysis, we determined optimal IFX concentration thresholds associated with treatment response. We further compared IFX induction concentrations between patients persisting on IFX at week 52 and patients discontinuing treatment due to insufficient response. Results: Responders (74%, 51 out of 69 patients) had significantly higher median IFX concentrations than non-responders at weeks 6 (25.06 vs. 19.68 µg/ml; P = 0.04) and 12 (18.03 vs. 10.02 µg/ml; P = 0.03), but not at week 2 (33.12 vs. 34.20 µg/ml; P = 0.97). Optimal IFX concentration thresholds for induction response were 21.33 and 5.13 µg/ml at weeks 6 and 12, respectively. Fifty-three patients continued IFX maintenance therapy until week 52. Induction concentrations failed to predict persistence on IFX therapy at week 52. Conclusion: Higher IFX induction concentrations predict endoscopic short-term response. However, induction concentrations failed to predict long-term persistence on IFX treatment.
- 10 September 2022
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 34 (11) , 1125-1131
Higher serum infliximab concentrations during induction predict short-term endoscopic response in patients with inflammatory bowel disease
Objective: Measuring of serum infliximab (IFX) induction concentrations might reduce primary non-response rates in inflammatory bowel diseases (IBD), but optimal target concentrations are unclear. We investigated whether IFX induction concentrations predict short-term endoscopic response at week 12 or treatment persistence at week 52. Methods: Sixty-nine IBD patients (Crohn’s disease, n=24; ulcerative colitis, n=45) received standard IFX induction of 5 mg/kg bodyweight at weeks 0, 2, and 6. Responders continued maintenance therapy and underwent follow-up until week 52 or treatment discontinuation. We measured IFX concentrations at weeks 2, 6, and 12, and evaluated treatment response around week 12 with endoscopy or with clinical scores and fecal calprotectin. Using the receiver operating characteristic analysis, we determined optimal IFX concentration thresholds associated with treatment response. We further compared IFX induction concentrations between patients persisting on IFX at week 52 and patients discontinuing treatment due to insufficient response. Results: Responders (74%, 51 out of 69 patients) had significantly higher median IFX concentrations than non-responders at weeks 6 (25.06 vs. 19.68 µg/ml; P = 0.04) and 12 (18.03 vs. 10.02 µg/ml; P = 0.03), but not at week 2 (33.12 vs. 34.20 µg/ml; P = 0.97). Optimal IFX concentration thresholds for induction response were 21.33 and 5.13 µg/ml at weeks 6 and 12, respectively. Fifty-three patients continued IFX maintenance therapy until week 52. Induction concentrations failed to predict persistence on IFX therapy at week 52. Conclusion: Higher IFX induction concentrations predict endoscopic short-term response. However, induction concentrations failed to predict long-term persistence on IFX treatment.
- Open Access
- 5 April 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (6) , 661-670
A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland
Real-world evidence to support optimal ustekinumab dosing for refractory Crohn’s disease (CD) patients remains limited. Data from a retrospective nationwide chart review study was utilized to explo...
- 5 April 2021
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 56 (6) , 661-670
Open AccessA nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland
Real-world evidence to support optimal ustekinumab dosing for refractory Crohn’s disease (CD) patients remains limited. Data from a retrospective nationwide chart review study was utilized to explo...
- Open Access
- 1 January 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (2) , e18723
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
Effectiveness, efficacy and safety of biosimilar infliximab (CT-P13) in inflammatory bowel disease (IBD) patients has been shown in previous studies. Limited data exist on health-related quality of life (HRQoL) of switching originator to biosimilar infliximab (IFX) in IBD patients. The objective of this study was to evaluate impact of switching originator to biosimilar IFX on HRQoL, disease activity, and health care costs in IBD maintenance treatment. In this single-center prospective observational study, all IBD patients receiving maintenance IFX therapy were switched to biosimilar IFX. HRQoL was measured using the generic 15D health-related quality of life instrument (15D) utility measurement and the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ). Crohn Disease Activity Index (CDAI) or Partial Mayo Score (pMayo), and fecal calprotectin (FC) served for evaluation of disease activity. Data were collected at time of switching and 3 and 12 months after switching. Patients’ characteristics, clinical background information and costs were collected from patient records and the hospital's electronic database. Fifty-four patients were included in the analysis. No statistically significant changes were observed in 15D, CDAI, pMayo, and FC during 1-year follow-up. IBDQ scores were higher (P = .018) in Crohn disease 3 months after switching than at time of switching. Costs of biosimilar IFX were one-third of costs of originator one. Total costs related to secondary health care (excluding costs of IFX), were similar before and after the onset of biosimilar IFX. HRQoL and disease activity were after switching from originator to biosimilar IFX comparable, but the costs of biosimilar IFX were only one-third of those of the originator one.
- 1 January 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (2) , e18723
Open AccessHealth-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease
Effectiveness, efficacy and safety of biosimilar infliximab (CT-P13) in inflammatory bowel disease (IBD) patients has been shown in previous studies. Limited data exist on health-related quality of life (HRQoL) of switching originator to biosimilar infliximab (IFX) in IBD patients. The objective of this study was to evaluate impact of switching originator to biosimilar IFX on HRQoL, disease activity, and health care costs in IBD maintenance treatment. In this single-center prospective observational study, all IBD patients receiving maintenance IFX therapy were switched to biosimilar IFX. HRQoL was measured using the generic 15D health-related quality of life instrument (15D) utility measurement and the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ). Crohn Disease Activity Index (CDAI) or Partial Mayo Score (pMayo), and fecal calprotectin (FC) served for evaluation of disease activity. Data were collected at time of switching and 3 and 12 months after switching. Patients’ characteristics, clinical background information and costs were collected from patient records and the hospital's electronic database. Fifty-four patients were included in the analysis. No statistically significant changes were observed in 15D, CDAI, pMayo, and FC during 1-year follow-up. IBDQ scores were higher (P = .018) in Crohn disease 3 months after switching than at time of switching. Costs of biosimilar IFX were one-third of costs of originator one. Total costs related to secondary health care (excluding costs of IFX), were similar before and after the onset of biosimilar IFX. HRQoL and disease activity were after switching from originator to biosimilar IFX comparable, but the costs of biosimilar IFX were only one-third of those of the originator one.
- 14 December 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 55 (1) , 34-40
Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases
Background and aims: A multicentre, retrospective, non-interventional, patient chart review study was conducted to investigate deep (DR) and histological remission rates during maintenance therapy with biological agents in inflammatory bowel disease (IBD). Methods: We reviewed clinical, endoscopic, and histological findings, and laboratory markers such as C-reactive protein (CRP) and faecal calprotectin (FC) on average of nine years after the initiation of anti-TNF-therapy. DR was defined as no clinical symptoms (The physicians’ global assessment scores; PGA = 0) with endoscopic remission (the Simple Endoscopic Score for Crohn’s Disease [SES-CD] ≤ 2 or Mayo endoscopic subscore ≤1). Histological activity was defined as normal if only architectural alterations without cellularity changes occurred. Results: Of 117 IBD patients on maintenance therapy, 72 (62%; CD n = 55 [56%], UC n = 17 [85%]) patients were in DR. Of patients in DR, 76% were also in histological remission. 77% of patients remained on initiated biological treatment. UC patients achieved DR significantly more often than CD patients (p = .016). Both median CRP and FC levels were significantly lower in patients with DR. Conclusion: Reassuringly, almost two thirds of the IBD patients on maintenance therapy with biological agents maintained DR in the long-term, and more than two thirds of patients in DR achieved also histological remission. CD patients in DR had fewer surgical operations due to CD than patients not achieving DR.
- 14 December 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 55 (1) , 34-40
Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases
Background and aims: A multicentre, retrospective, non-interventional, patient chart review study was conducted to investigate deep (DR) and histological remission rates during maintenance therapy with biological agents in inflammatory bowel disease (IBD). Methods: We reviewed clinical, endoscopic, and histological findings, and laboratory markers such as C-reactive protein (CRP) and faecal calprotectin (FC) on average of nine years after the initiation of anti-TNF-therapy. DR was defined as no clinical symptoms (The physicians’ global assessment scores; PGA = 0) with endoscopic remission (the Simple Endoscopic Score for Crohn’s Disease [SES-CD] ≤ 2 or Mayo endoscopic subscore ≤1). Histological activity was defined as normal if only architectural alterations without cellularity changes occurred. Results: Of 117 IBD patients on maintenance therapy, 72 (62%; CD n = 55 [56%], UC n = 17 [85%]) patients were in DR. Of patients in DR, 76% were also in histological remission. 77% of patients remained on initiated biological treatment. UC patients achieved DR significantly more often than CD patients (p = .016). Both median CRP and FC levels were significantly lower in patients with DR. Conclusion: Reassuringly, almost two thirds of the IBD patients on maintenance therapy with biological agents maintained DR in the long-term, and more than two thirds of patients in DR achieved also histological remission. CD patients in DR had fewer surgical operations due to CD than patients not achieving DR.
- Open Access
- 3 June 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (6) , 718-725
Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)
Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn’s Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patients receiving UST to provide guidance in UST treatment in the era of increasing prevalence of CD. Methods: The study assessed UST treatment patterns such as dosing frequency, concomitant medication and persistence in 48 CD patients commencing UST therapy in 12 Finnish hospitals during 2017. Clinical remission and response rates were explored using a modified Harvey–Bradshaw index (mHBI) and endoscopic response via the simple endoscopic score for Crohn’s disease (SES-CD) as proportions of patients at week 16 and at the end of follow-up. Results: Forty patients (83%) continued UST-treatment at the end of follow-up. At week 16, clinical response and endoscopic healing was observed, where data were available; mHBI decreased from 9 to 3 (p = .0001) and SES-CD from 12 to 3 (p = .009). Clinical benefit was achieved by 83% (19/23) at week 16 and by 76% (16/21) at the end of follow-up. The proportion of patients using corticosteroids decreased from 48% to 25% at week 16 and to 13% at the end of the follow-up. Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endoscopic response in this real-life nationwide study of CD patients. Significant corticosteroid tapering in patients with highly treatment refractory and long-standing CD was observed.
- 3 June 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (6) , 718-725
Open AccessUstekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)
Background: Ustekinumab (UST), a human anti-IL12/23p40 monoclonal antibody, has been approved for treatment of Crohn’s Disease (CD) since the end of 2016. This nationwide noninterventional, retrospective chart review explored real-life data in patients receiving UST to provide guidance in UST treatment in the era of increasing prevalence of CD. Methods: The study assessed UST treatment patterns such as dosing frequency, concomitant medication and persistence in 48 CD patients commencing UST therapy in 12 Finnish hospitals during 2017. Clinical remission and response rates were explored using a modified Harvey–Bradshaw index (mHBI) and endoscopic response via the simple endoscopic score for Crohn’s disease (SES-CD) as proportions of patients at week 16 and at the end of follow-up. Results: Forty patients (83%) continued UST-treatment at the end of follow-up. At week 16, clinical response and endoscopic healing was observed, where data were available; mHBI decreased from 9 to 3 (p = .0001) and SES-CD from 12 to 3 (p = .009). Clinical benefit was achieved by 83% (19/23) at week 16 and by 76% (16/21) at the end of follow-up. The proportion of patients using corticosteroids decreased from 48% to 25% at week 16 and to 13% at the end of the follow-up. Conclusion: UST showed to be effective and persistent, inducing short-term clinical benefit and endoscopic response in this real-life nationwide study of CD patients. Significant corticosteroid tapering in patients with highly treatment refractory and long-standing CD was observed.
- 27 March 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (4) , 414-418
Fragmented management of long-term parenteral support for adult intestinal failure in Finland
Objectives: Parenteral support (PS) is the first-line therapy for intestinal failure (IF). Optimal patient outcomes require experienced multidisciplinary teams adhering to structured protocols. As practices to provide long-term PS for adult IF patients in Finland are unknown, this cross-sectional nationwide study aimed to evaluate current management of PS for adult IF across the country. Materials and methods: An internet-based survey was emailed to all Finnish hospitals and hospital-at-home services with the potential to provide PS for adult IF. The survey included 20 items addressing the provision of long-term PS for adult IF patients (aged ≥18 years). Data were analysed using descriptive statistics. Results: Overall, 52 (47%) of the 111 identified units responded. Of responding units, 38 (73%) had at some point provided long-term (≥120 days) PS for adult IF, and 23 (44%) had done so during the preceding year. Only three units currently managed ≥3 adult patients. Most (65%) of the respondents worked in a hospital and were either physicians (38%) or dietitians (39%). Only 65% of respondents reported that their unit had an assigned physician responsible for PS provision, and 28% reported that a team was responsible for long-term PS. Only 26% of respondents reported having a written protocol to guide PS management. Conclusions: Health care providers with very limited experience and a fragmented approach manage most Finnish adult IF patients. Evidence-based protocols and multidisciplinary teams are scarce. The care for adult IF patients on long-term PS needs to be improved in Finland.
- 27 March 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (4) , 414-418
Fragmented management of long-term parenteral support for adult intestinal failure in Finland
Objectives: Parenteral support (PS) is the first-line therapy for intestinal failure (IF). Optimal patient outcomes require experienced multidisciplinary teams adhering to structured protocols. As practices to provide long-term PS for adult IF patients in Finland are unknown, this cross-sectional nationwide study aimed to evaluate current management of PS for adult IF across the country. Materials and methods: An internet-based survey was emailed to all Finnish hospitals and hospital-at-home services with the potential to provide PS for adult IF. The survey included 20 items addressing the provision of long-term PS for adult IF patients (aged ≥18 years). Data were analysed using descriptive statistics. Results: Overall, 52 (47%) of the 111 identified units responded. Of responding units, 38 (73%) had at some point provided long-term (≥120 days) PS for adult IF, and 23 (44%) had done so during the preceding year. Only three units currently managed ≥3 adult patients. Most (65%) of the respondents worked in a hospital and were either physicians (38%) or dietitians (39%). Only 65% of respondents reported that their unit had an assigned physician responsible for PS provision, and 28% reported that a team was responsible for long-term PS. Only 26% of respondents reported having a written protocol to guide PS management. Conclusions: Health care providers with very limited experience and a fragmented approach manage most Finnish adult IF patients. Evidence-based protocols and multidisciplinary teams are scarce. The care for adult IF patients on long-term PS needs to be improved in Finland.
- 1 March 2019
- Published by Elsevier in Biologicals
- Vol. 58, 50-56
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice
- 1 March 2019
- Published by Elsevier in Biologicals
- Vol. 58, 50-56
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice